InterCure to Release its Q2 2022 Results and Hold a Conference Call
InterCure (NASDAQ: INCR) plans to release its second-quarter financial results on August 15, 2022, post-market. The company, known for being Israel's largest licensed cannabis producer and a leader in the global cannabis market outside North America, emphasizes its high-margin, vertically integrated model. Following the results announcement, a live conference call will occur on August 16, 2022, at 8:30 AM ET to discuss the implications of the financial data.
- InterCure is recognized as Israel's largest licensed cannabis producer.
- The company operates a high-margin, vertically integrated 'seed-to-sale' model.
- None.
Conference call scheduled for Tuesday, August 16, 2022, at 8:30am ET
NEW YORK and TORONTO and HERZLIYA, Israel, Aug. 11, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) today announced that it plans to release financial results for the second quarter of 2022 after market close on Monday, August 15, 2022.
InterCure executives will host a live conference call and audio webcast to discuss these results on Tuesday, August 16, 2022, at 8:30 am Eastern Time, details of which are provided below.
To access the conference call, participants can register through the following URL: https://register.vevent.com/register/BI5e6af40482ac4b7bb3024b6aad2c8185.
Once registered participants will receive dials and a unique pin which will allow them to access the call.
A replay of the conference call will be available through the following Webcast link: https://edge.media-server.com/mmc/p/gm9sadgn, or through the ‘Events and Presentations’ section of the InterCure website at http://www.intercure.co.
About InterCure (dba Canndoc)
InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.
For more information, visit: http://www.intercure.co.
Contact:
InterCure Ltd.
Amos Cohen, Chief Financial Officer
amos@intercure.co
FAQ
When will InterCure release its second quarter 2022 financial results?
What time is InterCure's conference call scheduled for?
How can I access the conference call for InterCure?
What is the stock symbol for InterCure?
What is InterCure's business model?
